DRKS00016606已完成2 期
Specific anti hepatocellular carcinoma dendritic cells implantation as therapy or adjuvant treatment for patients with advanced hepatocellular carcinoma.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 45 Years 至 60 Years（—）
- 性别
- All
入选标准
- •According to Barcelona Clinic Liver Cancer (BCLC) staging system, stage B HCC patients not fit for resection or local ablative therapies, stage C HCC patients with portal vein thrombosis and stage D HCC patients with lymphatic or distant metastases are included.
排除标准
- •HCC patients (stage 0 and A) fit for radical or local ablation therapies or HCC patients with platelet count below 50,000 and or prothrombin activity below 50% were excluded from the study.
研究者
相似试验
已完成
不适用
Inhibition Effects of Hepatocellular Carcinoma Developments for Interferon-Free, Direct-Acting Antiviral Agents for Hepatitis C Virusthe patients with infected Hepatitis C virus(HCV)JPRN-UMIN000015933The Research Center for Hepatitis and Immunology National Center for Global Health and Medicine (NCGM)609
进行中（未招募）
不适用
Treatment of advanced hepatocellular carcinoma (HCC) with portal vein thrombosis by hepatic intra-arterial injection of microspheres loaded with Yttrium-90 (Thera-Sphere) - RAD-09advanced hepatocellular carcinoma (HCC) with portal vein thrombosisMedDRA version: 9.1Level: LLTClassification code 10024662MedDRA version: 9.1Level: PTClassification code 10019713EUCTR2009-016475-29-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
招募中
不适用
Sequential therapy for hepatocellular carcinoma -Real world evidence of TKI in prospective observational studyhepatocellular carcinomaJPRN-UMIN000038867Kyushu Study group of Clinical Cancer500
进行中（未招募）
2 期
Dendritic Cell Vaccination to Prevent Hepatocellular Carcinoma Recurrence After Liver Resection - Phase II Clinical TrialHepatocellular CarcinomaNCT06193733Chang Gung Memorial Hospital74
已完成
1 期
Dendritic cell-based tumor-specific immunotherapy against malignant brain tumor - Phase I clinical trialMalignant brain tumor (malignant glioma)JPRN-UMIN000000914Shizuoka Cancer Center12